107 results on '"Krishnan, J.A."'
Search Results
2. Proteomics of CT Emphysema Subtypes. The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
3. Effect of Smoking Cessation on COPD Exacerbations, Spirometry and Respiratory Symptoms in Spiromics
4. Cardiopulmonary Failure in Chronic Obstructive Pulmonary Disease (COPD): The Subpopulations and Intermediate Outcome Measures in COPD and Heart Failure Study (SPIROMICS HF)
5. Longitudinal Progression of CT Emphysema Subtypes Using Density-based and Hidden Markov Measure Field-based Thresholds: The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
6. Platelet Activation and Longitudinal Change in Percent Emphysema and Lung Function in Spiromics
7. Computer Assisted Quantitative Image Analysis as a Pathway to Identification of Combined Pulmonary Fibrosis and Emphysema (CPFE): Analysis of the SPIROMICS Cohort
8. COVID-19 Pandemic-associated Socioeconomic Vulnerability and Challenges to Isolation Across the United States
9. Requirements for Home Oxygen After Hospitalization for COVID-19 in 2020 and 2021: Results From the U.S. Oxford Multicenter Retrospective Cohort Study
10. Neighborhood-level Characteristics and Association With Alignment of Inhaled Medications in Chronic Obstructive Pulmonary Disease
11. Association of Hair Follicle Gene Expression With Airway Lumen Size and Wall Area on CT in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)
12. Serum Kynurenine/Tryptophan Ratio Is a Marker of Lung Disease Severity in Current and Former Tobacco Cigarette Users With and Without COPD
13. Deep Residual Convolutional Network Predicts Future Severe Exacerbations of COPD in SPIROMICS
14. Airway Epithelial Gene Expression Associated With Domains of Resilience in Smokers Without Airflow Obstruction
15. OXygen Status Following hOspitalization with cORonavirus Disease 2019 (OXFORD)
16. Associations of Serum and Bronchoalveolar Immunoglobulins with Lung Microbiota Diversity, B-Cell Memory Phenotypes, and COPD Morbidity and Exacerbations
17. Inhaled Medication Use in Ever Smokers With and Without a COPD Diagnosis in Primary Care: An Analysis of Prescribing Patterns in Electronic Medical Records
18. Eligibility for COPD Clinical Trials of Inhaled Triple Therapy: Analysis of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)
19. Clinical Practices Surrounding the Prescription of Home Oxygen with COPD and Desaturation
20. Genetic Regulators of Sputum Mucin Concentration Revealed by GWAS and Their Associations with Chronic Bronchitis and Acute Exacerbations of COPD
21. Association of Airway Tree Caliber with Airway Macrophage Black Carbon Content: The SubPopulations and InteRmediate Outcome Measures in COPD Air Pollution Study (SPIROMICS AIR)
22. Black Carbon Content in Airway Macrophages Is Associated with Worse COPD Patient-Reported Outcomes, FEV1 Decline, 6-Minute Walk Distance and a Higher Likelihood of Chronic Bronchitis in Current and Former Smokers from the SPIROMICS Cohort
23. Pharmacogenetic Determinants of Long-Acting Beta Agonist and Inhaled Corticosteroid Response in the AsthmaNet Best African Response to Drug Trial
24. Lung Structure and Risk of Sleep Apnea in SPIROMICS
25. Sex Differences in Longitudinal Assessment of COPD Morbidity in SPIROMICS
26. A Novel Approach to Medical Monitoring During the SARS-CoV-2 Pandemic Supporting the ACTIV 4B Outpatient Anticoagulation Trial
27. Characteristics of "Resilient Smokers" and Correlation with Biological Markers of COPD
28. Family History of Lung Disease Is Associated with Greater Severity of Patient-Reported Symptoms in COPD
29. Lung Volumes Differences Across GOLD Stages of COPD in VA Electronic Health Records, COPDGene, and SPIROMICS
30. Reduced Pneumococcal Antibody Function Is Associated with Exacerbations of COPD in SPIROMICS
31. Patient-Reported Clinical Variables Associated with Significant Air Trapping in Smokers: An Analysis of the SPIROMICS Cohort
32. Defining and Investigating "Resilience" to the Pulmonary Effects of Smoking in Spiromics
33. Evaluation of Hypoxemia Among Patients Admitted to a Tertiary Referral Hospital in Western Kenya
34. Association of Hospital Mortality and Readmission Rates in COPD Following Implementation of the Hospital Readmissions Reduction Program in the United States
35. Intermediate (CD14++ CD16+) Monocytes Correlate with Parametric Response Mapping of Functional Small Airways Disease: Spiromics Immunophenotyping Sub-Study
36. How Patients with COPD Decide Between Treatment Options and Implications for Pragmatic Trials Embedded in Clinical Care
37. Ambient Pollution Exposureand Sleep Quality in Spiromics
38. A Symptom-Based Approach to Defining Exacerbations Suggests High Burden of Exacerbation Events in SPIROMICS
39. Former and Current Smokers Living in High Poverty Neighborhoods Experience Heightened Adverse Respiratory Impacts of Ambient Ozone Exposure: An Analysis of Spiromics Air
40. Effect of Wearables on Sleep in Healthy Individuals: A Randomized Cross-Over Trial and Validation Study
41. Phenotypic Characteristics and Clinical Outcomes Among Individuals with COPD and Polycythemia
42. Medication Misuse, but Not Misdiagnosis, Is Associated with Older Age Among Patients Labeled with COPD
43. Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews
44. Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study
45. Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS
46. Quality standards in respiratory real-life effectiveness research: The REal Life EVidence AssessmeNt Tool (RELEVANT): Report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force
47. Alignment of inhaled chronic obstructive pulmonary disease therapies with published strategies :analysis of the Global Initiative for Chronic Obstructive Lung Disease recommendations in SpiroMics
48. Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis
49. Residential Segregation and COPD-Related Health Outcomes in SPIROMICS
50. Lung Microbiota Associations with Clinical Features of COPD in the SPIROMICS Cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.